March 9 (Reuters) - GSK said on Monday it will receive up to $690 million from Italian pharmaceutical company Alfasigma for ...

An increasing number of people are discovering fatty liver during routine ultrasound tests, often without any obvious symptoms. Doctors explain what this finding really means, why it is becoming more ...

The British pharma giant will hand off its experimental itch treatment to Italian company Alfasigma as it focuses on broader ...

Fatty liver is rising even among non-drinkers. A gastroenterologist explains the causes, lifestyle risks, early warning signs, and prevention tips for non-alcoholic fatty liver disease.

New molecular insights into the link between hepatocellular carcinoma and intratumoral fibrosis could lead to better ...

Researchers from The University of Osaka find that chronic liver congestion is linked to severe liver diseases through a specific signaling pathway in ...

Osteoporosis Bone Disease: Some diseases are so rare that they don't easily affect people, but once they do, they can be ...

Lysosomal Storage Disorders are genetic conditions caused by enzyme deficiencies that lead to harmful substance buildup in cells, resulting in progressive organ damage. Common disorders in India ...

Resmetirom improved HRQOL versus placebo in early MASH, particularly abdominal symptoms, disease-related worry, and health distress, with onset by week 24 and durability through week 52. Baseline ...

“When a doctor tells you it’s stage 4, you think, ‘My life is over,'" said Amy Piccioli ...

GSK has signed an eleventh-hour agreement to give Alfasigma rights to its primary biliary cholangitis (PBC) therapy linerixibat, which is under regulatory review in most major pharma markets worldwide ...

Ipilimumab-nivolumab also linked with better survival but more toxicity in small study ...